Search Results

There are 86281 results for: content related to: Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5

  1. Principles and practice of intraperitoneal chemotherapy for ovarian cancer

    International Journal of Gynecological Cancer

    Volume 17, Issue 1, January/February 2007, Pages: 1–20, K. FUJIWARA, D. ARMSTRONG, M. MORGAN and M. MARKMAN

    Version of Record online : 11 JAN 2007, DOI: 10.1111/j.1525-1438.2007.00809.x

  2. Inhibition of nuclear factor-κB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line

    International Journal of Gynecological Cancer

    Volume 16, Issue 5, September/October 2006, Pages: 1777–1782, G.H. LIU, S.R. WANG, B. WANG and B.H. KONG

    Version of Record online : 17 JUL 2006, DOI: 10.1111/j.1525-1438.2006.00652.x

  3. Combretastatin A-1 phosphate potentiates the antitumor activity of carboplatin and paclitaxel in a severe combined immunodeficiency disease (SCID) mouse model of human ovarian carcinoma

    International Journal of Gynecological Cancer

    Volume 16, Issue 4, July/August 2006, Pages: 1557–1564, K. STAFLIN, S. JÄRNUM, J. HUA, G. HONETH, P. KANNISTO and M. LINDVALL

    Version of Record online : 24 MAY 2006, DOI: 10.1111/j.1525-1438.2006.00627.x

  4. Combination paclitaxel (Taxol®)–cisplatin vs cyclophosphamide–cisplatin as primary therapy in patients with suboptimally debulked advanced ovarian cancer

    International Journal of Gynecological Cancer

    Volume 7, Issue s1, May 1997, Pages: 9–13, W. J. HOSKINS, W. P. MCGUIRE, M. F. BRADY, P. R. KUCERA, E. E. PARTRIDGE, K. Y. LOOK, D. L. CLARKE-PEARSON and M. DAVIDSON

    Version of Record online : 16 JUN 2003, DOI: 10.1046/j.1525-1438.7.s1.5.x

  5. Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens

    International Journal of Gynecological Cancer

    Volume 15, Issue 2, March 2005, Pages: 240–245, R. Uslu, U.A. Sanli, Y. Dikmen, B. Karabulut, A. Ozsaran, C. Sezgin, G.G. Muezzinoglu, S.B. Omay and E. Goker

    Version of Record online : 18 MAR 2005, DOI: 10.1111/j.1525-1438.2005.15210.x

  6. Hypoxia-inducible factor 1α (HIF-1α) correlated with tumor growth and apoptosis in ovarian cancer

    International Journal of Gynecological Cancer

    Volume 16, Issue S1, February 2006, Pages: 405–412, H. JIANG and Y. FENG

    Version of Record online : 24 FEB 2006, DOI: 10.1111/j.1525-1438.2006.00310.x

  7. Future options for first-line therapy of advanced ovarian cancer

    International Journal of Gynecological Cancer

    Volume 15, Issue s1, May 2005, Pages: 42–50, A. Du Bois and J Pfisterer

    Version of Record online : 11 APR 2005, DOI: 10.1111/j.1525-1438.2005.15356.x

  8. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5

    International Journal of Gynecological Cancer

    Volume 13, Issue s2, November 2003, Pages: 149–155, M. A. Bookman, B. E. Greer and R. F. Ozols

    Version of Record online : 18 DEC 2003, DOI: 10.1111/j.1525-1438.2003.13362.x

  9. Therapy-related myelodysplasia and acute myeloid leukemia following paclitaxel- and carboplatin-based chemotherapy in an ovarian cancer patient: a case report and literature review

    International Journal of Gynecological Cancer

    Volume 18, Issue 6, November/December 2008, Pages: 1371–1376, S. YEASMIN, K. NAKAYAMA, M. ISHIBASHI, A. ORIDE, A. KATAGIRI, I.N. PURWANA, K. IIDA, N. NAKAYAMA, H ISHIKURA and K. MIYAZAKI

    Version of Record online : 23 JAN 2008, DOI: 10.1111/j.1525-1438.2007.01185.x

  10. Cytokines IL-1β, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFα in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel

    International Journal of Gynecological Cancer

    Volume 10, Issue 1, January 2000, Pages: 33–41, R. T. Penson, K. Kronish, Z. Duan, A. J. Feller, P. Stark, S. E. Cook, L. R. Duska, A. F. Fuller, A. K. Goodman, N. Nikrui, K. M. MacNeill, U. A. Matulonis, F. I. Preffer and M. V. Seiden

    Version of Record online : 25 DEC 2001, DOI: 10.1046/j.1525-1438.2000.00003.x

  11. Combination paclitaxel (Taxol®)–carboplatin as first-line therapy for advanced ovarian cancer

    International Journal of Gynecological Cancer

    Volume 7, Issue s1, May 1997, Pages: 18–22, H. G. MEERPOHL

    Version of Record online : 16 JUN 2003, DOI: 10.1046/j.1525-1438.7.s1.6.x

  12. The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer

    International Journal of Gynecological Cancer

    Volume 11, Issue s1, July 2001, Pages: 21–30, J. B. Vermorken

    Version of Record online : 20 DEC 2001, DOI: 10.1046/j.1525-1438.2001.11(suppl.1)sup1021.x

  13. Effective desensitization protocol to paclitaxel following hypersensitivity reaction

    International Journal of Gynecological Cancer

    Volume 9, Issue 2, March/April 1999, Pages: 156–159, A. FISHMAN, T. GOLD, A. GOLDBERG, R. CONFINO-COHEN, Y. BEYTH, J. MENCZER and M. ALTARAS

    Version of Record online : 25 DEC 2001, DOI: 10.1046/j.1525-1438.1999.99014.x

  14. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer

    International Journal of Gynecological Cancer

    Volume 16, Issue 3, May/June 2006, Pages: 979–985, H. YAMAGUCHI, T. HISHINUMA, N. ENDO, H. TSUKAMOTO, Y. KISHIKAWA, M. SATO, Y. MURAI, M. HIRATSUKA, K. ITO, C. OKAMURA, N. YAEGASHI, N. SUZUKI, Y. TOMIOKA and J. GOTO

    Version of Record online : 13 JUN 2006, DOI: 10.1111/j.1525-1438.2006.00593.x

  15. You have free access to this content
    Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis

    International Journal of Cancer

    Volume 137, Issue 8, 15 October 2015, Pages: 2029–2039, Xiaoqian Yang, Jacson Shen, Yan Gao, Yong Feng, Yichun Guan, Zhan Zhang, Henry Mankin, Francis J. Hornicek and Zhenfeng Duan

    Version of Record online : 5 MAY 2015, DOI: 10.1002/ijc.29574

  16. High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature

    International Journal of Gynecological Cancer

    Volume 18, Issue 3, May/June 2008, Pages: 564–570, M. BAUR, B. FAZENY-DOERNER, S.J. OLSEN and C. DITTRICH

    Version of Record online : 16 AUG 2007, DOI: 10.1111/j.1525-1438.2007.01048.x

  17. Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in combination: a phase I trial in patients with recurrent ovarian cancer

    International Journal of Gynecological Cancer

    Volume 16, Issue 2, March/April 2006, Pages: 507–514, C.J. POOLE, T. PERREN, S. GAWANDE, M. RIDDERHEIM, J. COOK, A. JENKINS and D. ROYCHOWDHURY

    Version of Record online : 25 APR 2006, DOI: 10.1111/j.1525-1438.2006.00466.x

  18. First-line randomized trials: revisiting the Ptolemaic universe

    International Journal of Gynecological Cancer

    Volume 18, Issue s1, March/April 2008, Pages: 47–52, M.A. BOOKMAN

    Version of Record online : 2 SEP 2008, DOI: 10.1111/j.1525-1438.2007.01106.x

  19. What is the role of dose-dense therapy?

    International Journal of Gynecological Cancer

    Volume 15, Issue s3, November 2005, Pages: 233–240, M.E.L. van der BURG, A. Van Der GAAST, I. VERGOTE, C.W. BURGER, H.C. Van DOORN, R. De WIT, G. STOTER and J. VERWEIJ

    Version of Record online : 18 NOV 2005, DOI: 10.1111/j.1525-1438.2005.00432.x

  20. Outcomes for patients with fallopian tube carcinoma managed with adjuvant chemotherapy following primary surgery: a retrospective university experience

    International Journal of Gynecological Cancer

    Volume 17, Issue 5, September/October 2007, Pages: 998–1002, C.A. LEATH III, T.M. NUMNUM, J.M. STRAUGHN Jr, R.P. ROCCONI, W.K. HUH, L.C. KILGORE and E.E. PARTRIDGE

    Version of Record online : 15 MAR 2007, DOI: 10.1111/j.1525-1438.2007.00903.x